Regulation of Aryl Hydrocarbon Receptor Function by Selective Estrogen Receptor Modulators

Jemal, 2008, Cancer statistics, 2008., CA Cancer J Clin, 58, 71, 10.3322/CA.2007.0010

Hall, 1999, The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens., Endocrinology, 140, 5566, 10.1210/endo.140.12.7179

Howell, 2001, Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?, J Steroid Biochem Mol Biol, 79, 227, 10.1016/S0960-0760(01)00140-6

Vogel, 2009, The NSABP study of tamoxifen and raloxifene (STAR) trial., Expert Rev Anticancer Ther, 9, 51, 10.1586/14737140.9.1.51

Smith, 2004, Coregulator function: a key to understanding tissue specificity of selective receptor modulators., Endocr Rev, 25, 45, 10.1210/er.2003-0023

Norris, 1999, Peptide antagonists of the human estrogen receptor., Science, 285, 744, 10.1126/science.285.5428.744

Shang, 2000, Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription., Cell, 103, 843, 10.1016/S0092-8674(00)00188-4

Gundimeda, 1996, Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells., J Biol Chem, 271, 13504, 10.1074/jbc.271.23.13504

Lopes, 1990, Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain., Cancer Res, 50, 2753

Eisen, 2002, Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells., Mol Pharmacol, 62, 911, 10.1124/mol.62.4.911

Coward, 2001, 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ., Proc Natl Acad Sci USA, 98, 8880, 10.1073/pnas.151244398

Frasor, 2004, Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells., Cancer Res, 64, 1522, 10.1158/0008-5472.CAN-03-3326

Glidewell-Kenney, 2005, ERE-independent ERα target genes differentially expressed in human breast tumors., Mol Cell Endocrinol, 245, 53, 10.1016/j.mce.2005.10.003

Itoh, 2005, Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach., Mol Cancer Res, 3, 203, 10.1158/1541-7786.MCR-04-0122

Montano, 1997, The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens., Proc Natl Acad Sci USA, 94, 2581, 10.1073/pnas.94.6.2581

Denison, 1988, Inducible, receptor-dependent protein-DNA interactions at a dioxin-responsive transcriptional enhancer., Proc Natl Acad Sci USA, 85, 2528, 10.1073/pnas.85.8.2528

Klinge, 2000, The aryl hydrocarbon receptor interacts with estrogen receptor α and orphan receptors COUP-TFI and ERRα1., Arch Biochem Biophys, 373, 163, 10.1006/abbi.1999.1552

Wormke, 2003, The aryl hydrocarbon receptor mediates degradation of estrogen receptor α through activation of proteasomes., Mol Cell Biol, 23, 1843, 10.1128/MCB.23.6.1843-1855.2003

Hockings, 2006, The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen., Cancer Res, 66, 2224, 10.1158/0008-5472.CAN-05-1619

Khan, 2006, Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/Sp1 cross talk in breast cancer cells., Mol Endocrinol, 20, 2199, 10.1210/me.2006-0100

Tsuchiya, 2004, Human CYP1B1 is regulated by estradiol via estrogen receptor., Cancer Res, 64, 3119, 10.1158/0008-5472.CAN-04-0166

MacCallum, 2000, Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours., Br J Cancer, 82, 1629

Stearns, 2003, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine., J Natl Cancer Inst, 95, 1758, 10.1093/jnci/djg108

Cho, 2004, Disruption of cell-cell contact maximally but transiently activates AhR-mediated transcription in 10T1/2 fibroblasts., Toxicol Appl Pharmacol, 199, 220, 10.1016/j.taap.2003.12.025

Ikuta, 2004, Cell density regulates intracellular localization of aryl hydrocarbon receptor., J Biol Chem, 279, 19209, 10.1074/jbc.M310492200

Sindhu, 1996, Induction of cytochrome P4501A1 by photooxidized tryptophan in Hepa lclc7 cells., Biochem Pharmacol, 52, 1883, 10.1016/S0006-2952(97)81491-8

Ma, 2000, 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation of aryl hydrocarbon receptor (AhR) by the ubiquitin-proteasome pathway. Role of the transcription activaton and DNA binding of AhR., J Biol Chem, 275, 8432, 10.1074/jbc.275.12.8432

Lu, 1995, Identification of 3′-methoxy-4′-nitroflavone as a pure aryl hydrocarbon (Ah) receptor antagonist and evidence for more than one form of the nuclear Ah receptor in MCF-7 human breast cancer cells., Arch Biochem Biophys, 316, 470, 10.1006/abbi.1995.1062

Blank, 1987, α-Naphthoflavone antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced murine lymphocyte ethoxyresorufin-O-deethylase activity and immunosuppression., Mol Pharmacol, 32, 169

Merchant, 1990, The mechanism of action of α-naphthoflavone as an inhibitor of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 gene expression., Arch Biochem Biophys, 281, 84, 10.1016/0003-9861(90)90416-V

Swanson, 2002, DNA binding and protein interactions of the AHR/ARNT heterodimer that facilitate gene activation., Chem Biol Interact, 141, 63, 10.1016/S0009-2797(02)00066-2

Denison, 2003, Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals., Annu Rev Pharmacol Toxicol, 43, 309, 10.1146/annurev.pharmtox.43.100901.135828

Fukuda, 2007, Interaction between the aryl hydrocarbon receptor and its antagonists, flavonoids., Biochem Biophys Res Commun, 359, 822, 10.1016/j.bbrc.2007.05.199

Gradelet, 1997, Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and β-apo-8′-carotenal, with no affinity for the TCDD binding site., Biochem Pharmacol, 54, 307, 10.1016/S0006-2952(97)00176-7

Johnson, 2004, Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen., Breast Cancer Res Treat, 85, 151, 10.1023/B:BREA.0000025406.31193.e8

Lien, 1988, Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile., Cancer Res, 48, 2304

Lim, 2005, Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen., Cancer Chemother Pharmacol, 55, 471, 10.1007/s00280-004-0926-7

Furr, 1984, The pharmacology and clinical uses of tamoxifen., Pharmacol Ther, 25, 127, 10.1016/0163-7258(84)90043-3

Wu, 2009, The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells., Cancer Res, 69, 1722, 10.1158/0008-5472.CAN-08-3933

Borges, 2006, Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment., Clin Pharmacol Ther, 80, 61, 10.1016/j.clpt.2006.03.013

Meyers, 2001, Estrogen receptor-β potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues., J Med Chem, 44, 4230, 10.1021/jm010254a

Lund, 2005, Novel actions of estrogen receptor-β on anxiety-related behaviors., Endocrinology, 146, 797, 10.1210/en.2004-1158

Yu, 2006, Mechanism of cardioprotection following trauma-hemorrhagic shock by a selective estrogen receptor-β agonist: up-regulation of cardiac heat shock factor-1 and heat shock proteins., J Mol Cell Cardiol, 40, 185, 10.1016/j.yjmcc.2005.10.001

Lewis, 2008, Effects of estrogen receptor agonists on regulation of the inflammatory response in astrocytes from young adult and middle-aged female rats., J Neuroimmunol, 195, 47, 10.1016/j.jneuroim.2008.01.006

Ward, 1993, Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women., Bone Miner, 22, 87, 10.1016/S0169-6009(08)80220-6

Shevde, 2000, Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression., Proc Natl Acad Sci USA, 97, 7829, 10.1073/pnas.130200197

Teitelbaum, 2004, Postmenopausal osteoporosis, T cells, and immune dysfunction., Proc Natl Acad Sci USA, 101, 16711, 10.1073/pnas.0407335101

Voronov, 2005, Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration., Biochem Pharmacol, 70, 300, 10.1016/j.bcp.2005.04.028

Naruse, 2002, 3-Methylcholanthrene, which binds to the arylhydrocarbon receptor, inhibits proliferation and differentiation of osteoblasts in vitro and ossification in vivo., Endocrinology, 143, 3575, 10.1210/en.2002-220003

Ryan, 2007, Environmental toxicants may modulate osteoblast differentiation by a mechanism involving the aryl hydrocarbon receptor., J Bone Miner Res, 22, 1571, 10.1359/jbmr.070615

Hushka, 1998, Characterization of 2,3,7,8-tetrachlorodibenzofuran-dependent suppression and AH receptor pathway gene expression in the developing mouse mammary gland., Toxicol Appl Pharmacol, 152, 200, 10.1006/taap.1998.8508

Tsuchiya, 2005, Cytochrome P450-mediated metabolism of estrogens and its regulation in human., Cancer Lett, 227, 115, 10.1016/j.canlet.2004.10.007

Mooberry, 2003, New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent., Curr Opin Oncol, 15, 425, 10.1097/00001622-200311000-00004

Zahid, 2006, The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity., Chem Res Toxicol, 19, 164, 10.1021/tx050229y

Spink, 1998, Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells., Carcinogenesis, 19, 291, 10.1093/carcin/19.2.291

Robertson, 2005, Endocrine treatment options for advanced breast cancer–the role of fulvestrant., Eur J Cancer, 41, 346, 10.1016/j.ejca.2004.07.035

Chouinard, 2006, Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue., Mol Pharmacol, 69, 908, 10.1124/mol.105.015891

Erichsen, 2008, Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene., Toxicol Appl Pharmacol, 230, 252, 10.1016/j.taap.2008.02.020

Sun, 2007, Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases., Drug Metab Dispos, 35, 2006, 10.1124/dmd.107.017145

Cheung, 2008, Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment., J Pharmacol Exp Ther, 327, 288, 10.1124/jpet.108.141242

Connor, 2006, Human response to dioxin: aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR., J Toxicol Environ Health B Crit Rev, 9, 147, 10.1080/15287390500196487

Chalas, 2005, Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial., Am J Obstet Gynecol, 192, 1230, 10.1016/j.ajog.2004.12.083

Cohen, 1999, Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients., Gynecol Oncol, 72, 202, 10.1006/gyno.1998.5201

Gielen, 2008, Signaling by estrogens and tamoxifen in the human endometrium., J Steroid Biochem Mol Biol, 109, 219, 10.1016/j.jsbmb.2008.03.021

Collins, 2009, Characterization of antiestrogenic activity of the Chinese Herb, Prunella vulgaris, using in vitro and in vivo (mouse xenograft) models., Biol Reprod [Erratum (2009) 80:1306], 80, 375, 10.1095/biolreprod.107.065375

Kitajima, 2004, Histomorphometric alteration and cell-type specific modulation of arylhydrocarbon receptor and estrogen receptor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin and 17β-estradiol in mouse experimental model of endometriosis., Reprod Toxicol, 18, 793, 10.1016/j.reprotox.2004.04.012

Heilier, 2005, Increased dioxin-like compounds in the serum of women with peritoneal endometriosis and deep endometriotic (adenomyotic) nodules., Fertil Steril, 84, 305, 10.1016/j.fertnstert.2005.04.001

Nayyar, 2007, Developmental exposure of mice to TCDD elicits a similar uterine phenotype in adult animals as observed in women with endometriosis., Reprod Toxicol, 23, 326, 10.1016/j.reprotox.2006.09.007

Niskar, 2009, Serum dioxins, polychlorinated biphenyls, and endometriosis: a case-control study in Atlanta., Chemosphere, 74, 944, 10.1016/j.chemosphere.2008.10.005

Abbott, 1999, Adverse reproductive outcomes in the transgenic Ah receptor-deficient mouse., Toxicol Appl Pharmacol, 155, 62, 10.1006/taap.1998.8601

Fernandez-Salguero, 1995, Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor., Science, 268, 722, 10.1126/science.7732381

Gonzalez, 1998, The aryl hydrocarbon receptor: studies using the AHR-null mice., Drug Metab Dispos, 26, 1194

Hall, 2000, Development of peptide antagonists that target estrogen receptor β-coactivator interactions., Mol Endocrinol, 14, 2010

Oberg, 2005, Identification of the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, in cell culture medium, as a factor that controls the background aryl hydrocarbon receptor activity., Toxicol Sci, 85, 935, 10.1093/toxsci/kfi154

DuSell, 2008, 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator., Mol Endocrinol, 22, 65, 10.1210/me.2007-0383

Chan, 1994, Baculovirus expression of the Ah receptor and Ah receptor nuclear translocater. Evidence for additional dioxin responsive element-binding species and factors required for signaling., J Biol Chem, 269, 26464, 10.1016/S0021-9258(18)47217-1